Research on palliative care for blood cancers has surged in recent years, yet a new large-scale mapping study reveals persistent gaps in how this care reaches patients. The analysis, which examined 307 publications on palliative care in hematologic malignancies indexed in the databases Scopus and Web of Science from 2000 to 2026, shows that output accelerated after 2017 but remains concentrated in a small number of institutions, mostly in North America.
The study found that knowledge production grew at a descriptive annual rate of roughly 15 percent, with 258 articles appearing in the corpus. Yet only a handful of academic centers dominated the field, and international collaboration was limited. Seven palliative care journals accounted for the bulk of publications, while hematology journals carried far fewer. The most frequent keywords were palliative care, hematologic malignancies, quality of life, and communication.
A central finding concerns the collision of two vocabularies. One vocabulary centers on disease and treatment, including chemotherapy, survival, and mortality. The other centers on palliative care, including communication, integration, and goals of care. The mapping shows that disease-related terms entered the literature first, while palliative care terms arrived later, suggesting the two literatures have only recently begun to converge.
The study also identified a strong temporal pattern in the literature. Early publications focused on place of death, hospital mortality, and the technological imperative. Later work shifted toward communication, early integration, and quality of life. The most prominent bridging concept was early palliative care, which appeared in studies of acute myeloid leukemia and stem cell transplantation.
Uptake remains difficult because palliative care is still misconstrued as synonymous with hospice or end of life. The researchers note that this misconception persists among clinicians and patients alike, even as evidence accumulates that early involvement improves symptoms and quality of life. The 2024 American Society of Clinical Oncology guideline now recommends early concurrent palliative care alongside disease-directed therapy.
Advanced therapies have added new complexity. Chimeric antigen receptor T cell therapy and other cellular treatments create prolonged uncertainty about prognosis, making goals-of-care conversations harder to time. Studies of these therapies show high symptom burden and frequent hospitalizations, underscoring the need for concurrent palliative involvement.
The researchers also flagged persistent inequities. Rural populations face barriers to access, and studies show that people in rural areas are more likely to die in hospitals. The field has only recently begun to address these gaps, with the literature on rural access appearing in the last few years.
The team concluded that the literature has matured from a focus on technological care toward person-centered outcomes, but that translation into practice lags. They call for stronger integration of palliative care into hematology clinics, better timing of goals-of-care conversations, and more work on rural and underserved populations. The findings appear in a mapping study of palliative care in hematologic malignancies.
The bibliometric approach used in this study offers a distinctive lens compared with conventional systematic reviews. Rather than pooling clinical outcomes, the researchers mapped the structure of a scholarly field itself: who publishes, where, with whom, and on which themes. By combining VOSviewer visualization software with the bibliometrix package in the R statistical environment, the team could quantify patterns that individual narrative reviews tend to miss, such as the timing of keyword bursts, the density of co-citation networks, and the degree to which research communities overlap or remain siloed. The corpus of 307 publications, comprising 258 original articles and 49 reviews, was assembled from two major databases and subjected to a full-text verification step to ensure that the term palliative genuinely referred to palliative care rather than to non-curative chemotherapy or radiotherapy, a distinction that plagues searches in this domain.
The growth trajectory of the field is notable. Annual output rose at a descriptive rate of 17.6 percent across the study window, with a visible acceleration after 2017 and a peak of 49 publications in 2025. This timing coincides with several converging forces: the maturation of randomized evidence for early palliative care in oncology more broadly, the publication of professional society guidance emphasizing concurrent rather than terminal referral, and the expanding population of patients living longer with relapsed or refractory hematologic disease. The 2024 American Society of Clinical Oncology guideline, which recommends early concurrent specialist palliative care for patients with advanced cancer including hematologic malignancies, provides an anchor for this shift, and the bibliometric data suggest the literature has been responding to, rather than preceding, such recommendations.
The concentration of scholarship is striking. The United States alone produced 146 publications, more than the rest of the corpus combined, and international co-authorship accounted for only 14.98 percent of papers. Duke University and Harvard University emerged as the leading institutional contributors, and Thomas W. LeBlanc was identified as the most productive individual author. Journal placement reinforces this picture: seven palliative, supportive care, or hospice journals together published 38.8 percent of the corpus, while three leading hematology journals contributed only 19 articles. This distribution suggests that much of the work on palliative care in blood cancers is being read by palliative care specialists rather than by practicing hematologists and oncologists, potentially limiting cross-disciplinary uptake of findings that are most relevant at the point of hematologic treatment decisions.
The thematic evolution documented in the analysis mirrors a broader reorientation in palliative oncology. Keyword co-occurrence mapping, median publication years, and burst detection all indicated that recent publications increasingly address early palliative care, integration into disease-directed treatment, communication, quality of life, health care access, equity and disparities, and care delivered alongside hematopoietic stem-cell transplantation. Earlier work, by contrast, clustered around end-of-life patterns such as place of death and intensive care utilization near death. This shift reflects growing recognition that hematologic malignancies, because they often remain treatment-responsive late in their course, require palliative care models that run concurrently with active therapy rather than replacing it.
Several clinical realities help explain why integration in hematology lags behind solid-tumor oncology. Hematologic cancers are characterized by relapsing and unpredictable trajectories, repeated intensive therapy cycles, cytopenia-related complications, and serious infections, all of which impose a heavy symptom burden. At the same time, the possibility of cure or meaningful prolongation of life persists even at advanced stages, blurring the traditional transition point at which palliative care is introduced. Dependence on transfusions, antimicrobial therapy, and other life-sustaining measures complicates hospice enrollment, since many hospice eligibility frameworks were designed around solid tumors with clearer decline curves. Prognostic uncertainty is therefore not merely a communication challenge but a structural barrier to timely referral.
Evidence from interventional studies supports the value of earlier involvement. A randomized trial in hematopoietic cell transplantation demonstrated that inpatient palliative care attenuated early deterioration in quality of life and limited the worsening of psychological symptoms, findings that align with the broader early-palliative-care literature in advanced cancer. Yet the substantive literature synthesized in this review continues to describe late referral, intensive care near death, limited primary palliative care capacity within hematology teams, and unmet caregiver needs. The bibliometric findings suggest that while the research agenda has moved toward integration and communication, the problems those studies investigate remain unresolved in practice.
The authors are careful to delineate the limits of their methodology, and these limits matter for interpretation. Bibliometric analysis describes the structure and topics of a literature; it cannot establish clinical effectiveness, measure changes in practice, or determine whether growing publication volume translates into better patient outcomes. The descriptive growth rate is not a causal estimate, and database coverage in Web of Science Core Collection and Scopus may underrepresent work published in regional journals or by investigators outside high-income research systems. The restriction to English-language articles and reviews further narrows the visible landscape. These constraints are inherent to the method but are worth bearing in mind when weighing claims about field maturity or global reach.
The gaps the analysis identifies point toward a concrete research agenda. Community-based and rural palliative care delivery, caregiver support interventions, models for building primary palliative care skills among hematologists, equity-focused studies of access and disparities, and palliative transfusion practices all emerged as underrepresented topics relative to their clinical importance. International settings, particularly low- and middle-income countries where hematologic care infrastructure differs substantially, were largely absent from the collaboration networks. Because the corpus was concentrated in a small number of institutions and author groups, the field may benefit from deliberate diversification of research teams, funding priorities, and publication venues to ensure that findings generalize beyond the academic centers where they were generated.
For clinicians, the practical takeaway is that the evidence base for concurrent palliative care in hematology is growing but uneven, and that the barriers to integration are as much organizational and cultural as they are scientific. For researchers, the mapping provides a reference point for identifying where new work would be most additive. For patients and families navigating blood cancers, the study indirectly underscores a message that clinical guidelines have already made explicit: palliative care is not an alternative to treatment but a companion to it, and the timing of its involvement, rather than the stage of disease, is what the strongest evidence now supports.
Subject of Research: Palliative care in hematologic malignancies: a bibliometric review and visualization analysis from 2000 to 2025
Article Title: Palliative care in hematologic malignancies: a bibliometric review and visualization analysis from 2000 to 2025
Article References: Zeng, X., Yao, J., Mo, L., & Huang, X. (2026). Palliative care in hematologic malignancies: a bibliometric review and visualization analysis from 2000 to 2025. Frontiers in Oncology, 16, Article 1939505. https://doi.org/10.3389/fonc.2026.1939505
Image Credits: AI Generated
DOI: 10.3389/fonc.2026.1939505
Keywords: Palliative, care, hematologic, malignancies, bibliometric, review, visualization, analysis, scientific research
News Source: Ophelia Keating. (October 17, 2026). Palliative care in hematologic malignancies: a bibliometric review and visualization analysis from 2000 to 2025. Scienmag.
